📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant. (2021)

First Author: Reuschl AK

Attributed to: Characterisation and therapeutic manipulation of Flaviviridae innate immune evasion funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1101/2021.01.24.427991

PubMed Identifier: 33501437

Publication URI: http://europepmc.org/abstract/MED/33501437

Type: Journal Article/Review

Parent Publication: bioRxiv : the preprint server for biology

ISSN: 2692-8205